Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hopes Rise For Approval Of Melanoma Drug Ipilimumab, With Positive Front-line Results

This article was originally published in The Pink Sheet Daily

Executive Summary

As Bristol-Myers' ipilimumab nears its March 26 PDUFA date for second-line melanoma, drug demonstrates good results in front-line study. Will the data sway regulators?

You may also be interested in...



Protecting The Blind: FDA, BMS Took Pains To Ensure Integrity Of Ongoing Yervoy Study

FDA and Bristol-Myers Squibb went to great lengths to ensure that interim overall survival data from a first-line study of Yervoy (ipilimumab) could be reviewed by the agency in a manner that maintained the trial’s blind.

Protecting The Blind: FDA, BMS Took Pains To Ensure Integrity Of Ongoing Yervoy Study

FDA and Bristol-Myers Squibb went to great lengths to ensure that interim overall survival data from a first-line study of Yervoy (ipilimumab) could be reviewed by the agency in a manner that maintained the trial’s blind.

Yervoy Approval Has Shifted Development Landscape For Melanoma

With Bristol-Myers Squibb Co.’s ipilimumab cleared and Roche/Daiichi Sankyo’s BRAF inhibitor vemurafenib (RG7204) on track for a filing and perhaps approval this year, companies developing other melanoma drugs face a more complicated, competitive path to market.

Related Content

Topics

UsernamePublicRestriction

Register

OM006051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel